CASE REPORT
The onset of Graves’ disease during the clinical course of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis
Isao Ohsawa1, 3 , Yoshinobu Fuke2, Atsushi Satomura2, Hiroaki Hamada1, Katsuhiko Furuta1, Toshiharu Maruyama1, Sukemasa Sudo1 and Hiroyuki Ohi1
| (1) |
Kasukabe Kisen Hospital, Kasukabe 344-0067, Japan |
| (2) |
Department of Nephrology, Nihon University School of Medicine, Tokyo, Japan |
| (3) |
Present address: Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan |
Received: 08 March 2005 Accepted: 23 May 2005
Full Text
> Click Here （member's only）
Abstract A 47-year old man presented with atrial fibrillation, weight loss, hand tremor, and hyperperspiration concurrent with the reactivation of the disease activity of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis. Laboratory findings indicated that the hyperthyroidism had already existed when glomerulonephritis was detected, and Graves’ disease became evident while decreasing the dose of prednisolone. Although the levels of thyroid-stimulating hormone receptor antibody, antithyroid peroxidase antibody, and myeloperoxidase antibody increased, both disease activities were suppressed by increasing the dose of prednisolone. This case indicates that MPO-ANCA-associated glomerulonephritis and Graves’ disease may share a common pathogenesis.
Key words Antithyroid peroxidase (TPO) antibody - Crescentic glomerulonephritis (GN) - Graves’ disease - Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)
